The Assembly yesterday passed a bill regulating how biosimilar medications are dispensed -- in advance of biosimilars themselves. The new type of biologic drug is not currently sold, marketed or approved for the U.S. market. That's one of the problems cited by opponents of the bill. Read more here.
